Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein
Science Immunology · 31.03.2023 · 8 (81)
DOI: 10.1126/sciimmunol.ade0958 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 31.03.2023. Verfasst von Filippo Bianchini und 45 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, COVID-19. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, Swiss National Science Foundation.
Abstract (Originalsprache)
Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued development of immunotherapies and vaccine immunogens resilient to viral evolution is therefore necessary. Using coldspot-guided antibody discovery, a screening approach that focuses on portions of the virus spike glycoprotein that are both functionally relevant and averse to change, we identified human neutralizing antibodies to highly conserved viral epitopes. Antibody fp.006 binds the fusion peptide and cross-reacts against coronaviruses of the four genera, including the nine human coronaviruses, through recognition of a conserved motif that includes the S2′ site of proteolytic cleavage. Antibody hr2.016 targets the stem helix and neutralizes SARS-CoV-2 variants. Antibody sd1.040 binds to subdomain 1, synergizes with antibody rbd.042 for neutralization, and, similar to fp.006 and hr2.016, protects mice expressing human angiotensin-converting enzyme 2 against infection when present as a bispecific antibody. Thus, coldspot-guided antibody discovery reveals donor-derived neutralizing antibodies that are cross-reactive with Orthocoronavirinae, including SARS-CoV-2 variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
- Department of Biology, Stanford University, Stanford, CA, USA.
- Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic.
- Veterinary Research Institute, Brno, Czech Republic.
- Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.
- Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
ORCID-Profile: Filippo Bianchini, Virginia Crivelli, Concetta Guerra, Martin Palus, Harold Marcotte, Antonio Piralla, Mattia Pedotti, Raoul De Gasparo, Milos Matkovic, Chiara Toscano, Pavel Svoboda, Tomás Cervantes Rincón, Tommaso Fava, Lucie Podešvová, Akanksha A Shanbhag, Andrea Celoria, Michal Stefanik, Vaclav Hönig, Veronika Pranclova, Tereza Michalcikova, Giuditta Guerrini, Dora Mehn, Annalisa Ciabattini, Hassan Abolhassani, David Jarrossay, Mariagrazia Uguccioni, Qiang Pan-Hammarström, Luigi Calzolai, Daniel Fernandez, Fausto Baldanti, Alessandra Franzetti-Pellanda, Christian Garzoni, Radislav Sedlacek, Daniel Ruzek, Luca Varani, Andrea Cavalli, Christopher O Barnes, Davide F Robbiani
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- Swiss National Science Foundation
Zitieren
APA
Bianchini, F., Crivelli, V., Abernathy, M. E., Guerra, C., Palus, M., Muri, J., Marcotte, H., Piralla, A., Pedotti, M., De Gasparo, R., Simonelli, L., Matkovic, M., Toscano, C., Biggiogero, M., Calvaruso, V., Svoboda, P., Cervantes Rincón, T., Fava, T., Podešvová, L., …, & Robbiani, D. F. (2023). Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein. Science Immunology, 8(81). https://doi.org/10.1126/sciimmunol.ade0958
Vancouver
Bianchini F, Crivelli V, Abernathy ME, Guerra C, Palus M, Muri J, et al. Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein. Science Immunology. 2023;8(81). doi:10.1126/sciimmunol.ade0958
BibTeX
@article{Bianchini2023,
author = {Bianchini, Filippo and Crivelli, Virginia and Abernathy, Morgan E and Guerra, Concetta and Palus, Martin and Muri, Jonathan and Marcotte, Harold and Piralla, Antonio and Pedotti, Mattia and De Gasparo, Raoul and Simonelli, Luca and Matkovic, Milos and Toscano, Chiara and Biggiogero, Maira and Calvaruso, Veronica and Svoboda, Pavel and Cervantes Rincón, Tomás and Fava, Tommaso and Podešvová, Lucie and Shanbhag, Akanksha A and Celoria, Andrea and Sgrignani, Jacopo and Stefanik, Michal and Hönig, Vaclav and Pranclova, Veronika and Michalcikova, Tereza and Prochazka, Jan and Guerrini, Giuditta and Mehn, Dora and Ciabattini, Annalisa and Abolhassani, Hassan and Jarrossay, David and Uguccioni, Mariagrazia and Medaglini, Donata and Pan-Hammarström, Qiang and Calzolai, Luigi and Fernandez, Daniel and Baldanti, Fausto and Franzetti-Pellanda, Alessandra and Garzoni, Christian and Sedlacek, Radislav and Ruzek, Daniel and Varani, Luca and Cavalli, Andrea and Barnes, Christopher O and Robbiani, Davide F},
title = {Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein},
journal = {Science Immunology},
year = {2023},
volume = {8},
number = {81},
doi = {10.1126/sciimmunol.ade0958}
}
EUVIMED